We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+57.35%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.79B
AUM Growth
+$267M
Cap. Flow
-$147M
Cap. Flow %
-8.23%
Top 10 Hldgs %
60.02%
Holding
83
New
11
Increased
14
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$33.6M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$26.3M
3
CBAY
Cymabay Therapeutics
CBAY
+$23.5M
4
PCVX icon
Vaxcyte
PCVX
+$18.5M
5
EYPT icon
EyePoint Inc
EYPT
+$18.2M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$178M
2
PLRX icon
Pliant Therapeutics
PLRX
+$38.4M
3
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$26M
4
ETNB
89bio
ETNB
+$25.5M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$22.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.17%
2 Financials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
26
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$17.3M 0.97%
80,000
– –
LBPH
27
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$17.3M 0.97%
2,353,141
– –
RCKT icon
28
Rocket Pharmaceuticals
RCKT
$380M
$17.3M 0.97%
868,550
– –
AXNX
29
DELISTED
Axonics, Inc. Common Stock
AXNX
$16.3M 0.91%
322,240
– –
SRPT icon
30
Sarepta Therapeutics
SRPT
$1.75B
$14.9M 0.83%
130,000
+20,000
+18% +$2.58M
PHVS icon
31
Pharvaris
PHVS
$2.43B
$14.7M 0.83%
973,614
+157,154
+19% +$1.52M
IDYA icon
32
IDEAYA Biosciences
IDYA
$3.51B
$14.1M 0.79%
600,000
+250,000
+71% +$5.14M
BBIO icon
33
PUT
BridgeBio Pharma
BBIO
$16.2B
$13.9M 0.78%
+810,800
New +$12.2M
COGT icon
34
Cogent Biosciences
COGT
$7.23B
$11.8M 0.66%
1,000,000
+300,000
+43% +$3.44M
ISEE
35
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$11.8M 0.66%
+300,000
New +$10.6M
STOK icon
36
Stoke Therapeutics
STOK
$2.08B
$11.6M 0.65%
1,087,807
– –
PRAX icon
37
Praxis Precision Medicines
PRAX
$9.92B
$10.9M 0.61%
+633,333
New +$9.7M
IMVT icon
38
Immunovant
IMVT
$8.1B
$10.4M 0.58%
+550,000
New +$10.3M
IRON icon
39
Disc Medicine
IRON
$2.97B
$9.99M 0.56%
+225,000
New +$7.98M
RYTM icon
40
Rhythm Pharmaceuticals
RYTM
$7.82B
$9.89M 0.55%
+600,000
New +$10.8M
LIAN
41
DELISTED
LianBio American Depositary Shares
LIAN
$9.69M 0.54%
4,250,000
– –
MORF
42
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$8.6M 0.48%
150,000
-175,000
-54% -$9.14M
ATXS
43
DELISTED
Astria Therapeutics
ATXS
$8.33M 0.47%
1,000,000
– –
ARQT icon
44
Arcutis Biotherapeutics
ARQT
$3.23B
$7.62M 0.43%
+800,000
New +$8.88M
GHRS icon
45
GH Research
GHRS
$2.06B
$7.04M 0.39%
593,043
– –
VERV
46
DELISTED
Verve Therapeutics
VERV
$6.56M 0.37%
350,000
– –
RAPT
47
DELISTED
RAPT Therapeutics
RAPT
$6.08M 0.34%
40,625
-40,625
-50% -$6.33M
VIGL
48
DELISTED
Vigil Neuroscience
VIGL
$5.8M 0.32%
616,786
– –
AVIR icon
49
Atea Pharmaceuticals
AVIR
$408M
$5.79M 0.32%
1,547,181
– –
AKRO
50
DELISTED
Akero Therapeutics
AKRO
$5.37M 0.3%
+115,000
New +$5.27M
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Cormorant Asset Management held 83 positions worth $1.79B, up 18% from $1.52B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Cormorant Asset Management withdrew a net $147M in Q2 2023, closing 19 positions and reducing 6 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $178M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Zentalis Pharmaceuticals worth $30.9M.

  • Cormorant Asset Management's largest Q2 2023 buy was Zentalis Pharmaceuticals: 1,095,000 shares worth $30.9M.
  • Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q2 2023, an estimated $33.6M increase.
  • Cormorant Asset Management's biggest Q2 2023 reduction was 89bio, cutting an estimated $25.5M.
  • Cormorant Asset Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $178M.
  • Cormorant Asset Management's ten largest holdings make up 60% of its $1.79B portfolio in Q2 2023.
  • Cormorant Asset Management opened 11 new positions and closed 19 in Q2 2023.
  • Cormorant Asset Management's portfolio value rose 18% quarter-over-quarter to $1.79B.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.